INSILENS, A Noetera Company Biotech Intelligence Platform Turn Global Biotech Signals, Into Strategic Intelligence Explore with us Biotech Signals. Structured for Decisions. INSILENS converts global biotech activity into decision-grade intelligence for investors, executives, and business development teams. Deals and Financing ❮ Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding April 1, 2026 Alltrna / tRNA Therapy – First Clinical Trial Approaching for Nonsense Mutation Diseases April 1, 2026 Tempest Therapeutics – CAR-T Expansion and TPST-2003 Interim Data in Multiple Myeloma April 1, 2026 Fortress Biotech, $205M Priority Review Voucher Sale April 16, 2021 ❯ Therapeutic Indication ❮ Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding April 1, 2026 Alltrna / tRNA Therapy – First Clinical Trial Approaching for Nonsense Mutation Diseases April 1, 2026 Tempest Therapeutics – CAR-T Expansion and TPST-2003 Interim Data in Multiple Myeloma April 1, 2026 Fortress Biotech, $205M Priority Review Voucher Sale April 16, 2021 ❯ Technology Modalities ❮ Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding April 1, 2026 Alltrna / tRNA Therapy – First Clinical Trial Approaching for Nonsense Mutation Diseases April 1, 2026 Tempest Therapeutics – CAR-T Expansion and TPST-2003 Interim Data in Multiple Myeloma April 1, 2026 Fortress Biotech, $205M Priority Review Voucher Sale April 16, 2021 ❯ View all
Alltrna / tRNA Therapy – First Clinical Trial Approaching for Nonsense Mutation Diseases April 1, 2026
Alltrna / tRNA Therapy – First Clinical Trial Approaching for Nonsense Mutation Diseases April 1, 2026
Alltrna / tRNA Therapy – First Clinical Trial Approaching for Nonsense Mutation Diseases April 1, 2026